Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 3
2001 2
2003 1
2005 1
2006 2
2007 1
2008 1
2009 1
2010 2
2011 1
2012 1
2016 1
2017 2
2019 2
2020 8
2021 10
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Enhanced antibody half-life improves in vivo activity.
Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Zalevsky J, et al. Nat Biotechnol. 2010 Feb;28(2):157-9. doi: 10.1038/nbt.1601. Epub 2010 Jan 17. Nat Biotechnol. 2010. PMID: 20081867 Free PMC article.
Engineering IL-2 to Give New Life to T Cell Immunotherapy.
Overwijk WW, Tagliaferri MA, Zalevsky J. Overwijk WW, et al. Among authors: zalevsky j. Annu Rev Med. 2021 Jan 27;72:281-311. doi: 10.1146/annurev-med-073118-011031. Epub 2020 Nov 6. Annu Rev Med. 2021. PMID: 33158368 Free article. Review.
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
Diab A, Tykodi SS, Daniels GA, Maio M, Curti BD, Lewis KD, Jang S, Kalinka E, Puzanov I, Spira AI, Cho DC, Guan S, Puente E, Nguyen T, Hoch U, Currie SL, Lin W, Tagliaferri MA, Zalevsky J, Sznol M, Hurwitz ME. Diab A, et al. Among authors: zalevsky j. J Clin Oncol. 2021 Sep 10;39(26):2914-2925. doi: 10.1200/JCO.21.00675. Epub 2021 Jul 13. J Clin Oncol. 2021. PMID: 34255535 Free PMC article. Clinical Trial.
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Siefker-Radtke AO, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Hurwitz ME, Tannir NM. Siefker-Radtke AO, et al. Among authors: zalevsky j. Eur Urol. 2022 Oct;82(4):365-373. doi: 10.1016/j.eururo.2022.05.002. Epub 2022 May 25. Eur Urol. 2022. PMID: 35643589 Clinical Trial.
NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy.
Miyazaki T, Maiti M, Hennessy M, Chang T, Kuo P, Addepalli M, Obalapur P, Sheibani S, Wilczek J, Pena R, Quach P, Cetz J, Moffett A, Tang Y, Kirk P, Huang J, Sheng D, Zhang P, Rubas W, Madakamutil L, Kivimäe S, Zalevsky J. Miyazaki T, et al. Among authors: zalevsky j. J Immunother Cancer. 2021 May;9(5):e002024. doi: 10.1136/jitc-2020-002024. J Immunother Cancer. 2021. PMID: 34001523 Free PMC article.
Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in Rodents.
Kopruszinski CM, Swiokla J, Lee YS, Navratilova E, VanderVeen L, Yang M, Liu Y, Miyazaki T, Schmidt WK, Zalevsky J, Porreca F. Kopruszinski CM, et al. Among authors: zalevsky j. Cell Mol Neurobiol. 2021 Jul;41(5):949-960. doi: 10.1007/s10571-020-00816-3. Epub 2020 Feb 27. Cell Mol Neurobiol. 2021. PMID: 32107752
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
Tannir NM, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Siefker-Radtke AO, Hurwitz ME. Tannir NM, et al. Among authors: zalevsky j. J Immunother Cancer. 2022 Apr;10(4):e004419. doi: 10.1136/jitc-2021-004419. J Immunother Cancer. 2022. PMID: 35444058 Free PMC article. Clinical Trial.
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.
Sharma M, Khong H, Fa'ak F, Bentebibel SE, Janssen LME, Chesson BC, Creasy CA, Forget MA, Kahn LMS, Pazdrak B, Karki B, Hailemichael Y, Singh M, Vianden C, Vennam S, Bharadwaj U, Tweardy DJ, Haymaker C, Bernatchez C, Huang S, Rajapakshe K, Coarfa C, Hurwitz ME, Sznol M, Hwu P, Hoch U, Addepalli M, Charych DH, Zalevsky J, Diab A, Overwijk WW. Sharma M, et al. Among authors: zalevsky j. Nat Commun. 2020 Jan 31;11(1):661. doi: 10.1038/s41467-020-14471-1. Nat Commun. 2020. PMID: 32005826 Free PMC article. Clinical Trial.
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist.
Parisi G, Saco JD, Salazar FB, Tsoi J, Krystofinski P, Puig-Saus C, Zhang R, Zhou J, Cheung-Lau GC, Garcia AJ, Grasso CS, Tavaré R, Hu-Lieskovan S, Mackay S, Zalevsky J, Bernatchez C, Diab A, Wu AM, Comin-Anduix B, Charych D, Ribas A. Parisi G, et al. Among authors: zalevsky j. Nat Commun. 2020 Jan 31;11(1):660. doi: 10.1038/s41467-019-12901-3. Nat Commun. 2020. PMID: 32005809 Free PMC article.
NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential.
Miyazaki T, Choi IY, Rubas W, Anand NK, Ali C, Evans J, Gursahani H, Hennessy M, Kim G, McWeeney D, Pfeiffer J, Quach P, Gauvin D, Riley TA, Riggs JA, Gogas K, Zalevsky J, Doberstein SK. Miyazaki T, et al. Among authors: zalevsky j. J Pharmacol Exp Ther. 2017 Oct;363(1):104-113. doi: 10.1124/jpet.117.243030. Epub 2017 Aug 4. J Pharmacol Exp Ther. 2017. PMID: 28778859
38 results